藥易購(300937.SZ):董事兼總經理詹德妍辭職
格隆匯1月28日丨藥易購(300937.SZ)公佈,公司近日收到公司董事兼總經理詹德妍、董事兼副總經理劉然提交的書面辭職報吿。詹德妍因個人原因,申請辭去公司總經理、第二屆董事會董事和薪酬考核委員會委員職務,劉然申請辭去公司副總經理職務。
詹德妍原定任期為2019年6月21日至2022年6月21日,劉然原定任期為2021年4月15日至2022年6月21日。根據《公司法》和《公司章程》等有關規定,其二人的辭職申請自書面辭職報吿送達公司董事會之日起生效。詹德妍辭去總經理、第二屆董事會董事和薪酬考核委員會委員後,不再擔任公司任何職務;劉然辭去副總經理職務後將繼續擔任公司第二屆董事會董事、副董事長以及第二屆董事會審計委員會委員,除此之外將不再擔任公司其他任何職務。詹德妍的辭職,不會導致公司董事會成員低於法定最低人數,其二人辭職不會對公司的正常經營運作產生影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.